RE: CE Approval22 Feb 2021 21:40
Hi LordPaul,
My pleasure.
Great Times Ahead for All GDR Shareholders, we have so much Great News coming our way:-
GDR Valuation of COVID Tests:
Extract from my post on 12th Sept: - GDR Conservative Potential: -
I believe that GDR Mcap is potentially worth £300 mil Mcap, based on projected Sales and Profit.
I expect GDR to sell 50,000 RT-PCR Test units/day at £10 per Test = £500,000 per day revenue at 60% profit margin = £300,000 per day profit.
Working on a 5 day week = 5 x £300,000 = £1,500,000 profit per week.
£1,500,000 x 50 wks per year = £75,000,000 profit per year.
Using a standard multiple of 4 for valuation = 4 x £75,000,000 = Mcap of £300,000,000
Mcap of £300,000,000 divided by 52,000,000 shares = a potential SP of £5.77p
This Mcap valuation does not take into consideration a valuation of our POC; HCV. DOD or AIHL etc
Taking into consideration BGF conversion of their Loan Note to Shares, means our Total Share in Market will rise to 64,000,000 Shares.
Therefore - £300,000,000 divided by 64,000,000 shares = a potential £4.68p SP !
bigAl67
Posted in: GDR
Posts: 677
Price: 103.00
No Opinion
RE: Roll on November RNS30 Oct 2020 16:46
Africa; India and USA are our Targeted Markets, and this is why DB has cleverly chosen these markets: The recent Beckman Coulter Distribution Agreement brings Europe back into a Targeted Market too !!
Population of Africa 2020 = 1,348,301,517
Population of India 2020 = 1,380,004,385
Population of USA 2020 = 331,000,000
Population of Europe 2021 = 747,928,877
Massive new cases and deaths in Africa; India and USA, and these Countries will need GDR/BC Tests !
COVID Tests will be with us for many years to come, way past COVID Vaccine World wide availability, IMHO.
Sign In
Follow the stocks
